Ontology highlight
ABSTRACT:
SUBMITTER: Clemens PL
PROVIDER: S-EPMC5511594 | biostudies-literature | 2017 Aug
REPOSITORIES: biostudies-literature
Clemens Pamela L PL Yan Xiaoyu X Lokhorst Henk M HM Lonial Sagar S Losic Nedjad N Khan Imran I Jansson Richard R Ahmadi Tahamtan T Lantz Kristen K Zhou Honghui H Puchalski Thomas T Xu Xu Steven XS
Clinical pharmacokinetics 20170801 8
Daratumumab is a CD38 monoclonal antibody recently approved for the treatment of multiple myeloma (MM). We report daratumumab pharmacokinetic data from GEN501, a phase I/II dose-escalation (0.005-24 mg/kg) and dose-expansion (8 or 16 mg/kg) study, and SIRIUS, a phase II study (8 or 16 mg/kg), in relapsed or refractory MM. Noncompartmental analysis was conducted to characterize daratumumab pharmacokinetics, and, in both studies, daratumumab exhibited nonlinear pharmacokinetic characteristics. Dec ...[more]